Latest news with #COSM
Yahoo
09-04-2025
- Business
- Yahoo
Final details laid out for Gilbert's next development in downtown Detroit
Dan Gilbert's real estate firm has finalized the details of its long-in-the-works Monroe Blocks development in downtown Detroit, now set to begin construction next week. Bedrock's chief lobbyist, Jared Fleisher, laid out the development's latest two-phase plan Wednesday afternoon for members of the Downtown Development Authority, who unanimously approved it. Now called The Development at Cadillac Square, the development has been significantly scaled back from an original, $800 million-plus version dating to before the COVID-19 pandemic that was heavy on new office buildings and never got started. This latest version is also a bit smaller than a 2023 iteration that included a third phase, 'We've consolidated and simplified the plan into two phases,' Fleisher said. 'COVID changed this downtown and downtowns across the country. It's all about growing our residential population and creating the kind of entertainment amenities that are the new lifeblood of our downtown, because banking on office ain't gonna do it." More: Red Arrow Lofts open in former Detroit bottling plant More: Rocket Companies to buy Texas mortgage servicing firm Mr. Cooper in $9.4B deal A groundbreaking is scheduled for April 17 on the first component of the revised project's initial phase: a 70,000-square-foot venue for ultra-high-definition viewing of sports and other live events, known as COSM Detroit. The venue will go at the corner of Monroe Street and Campus Martius, on the previous site of the "Monroe Street Midway." It would have seating for 700 people under its "shared reality dome," with an adjacent lounge, dining hall and outdoor deck bringing total capacity to about 1,500. Fleisher also revealed that the second component of the initial phase, to be built next to COSM, will be a 34,000-square-foot Market Hall. The Market Hall would be developed by London-based The Venue Group and feature an array of local restaurant concepts, local retail brands and space for live music. COSM and the Market Hall are expected to draw tens of thousands of people to downtown every month, he said. The development's second phase must break ground by Oct. 1, 2026, under the newly approved DDA agreement. It calls for construction of new housing — between 250 to 280 units — as well as 42,000 square-feet of new retail space. The second phase also calls for a new parking structure with 950 to 1,100 spaces. The development plan no longer includes a third phase, which was to have some 400,000 feet of office space and an additional 17,000 square feet of retail, and get started by January 2028. The Monroe Blocks was one of four Bedrock projects in downtown approved in 2018 for a then-new Transformational Brownfield development incentive, collectively worth up to $618 million. The others are the still-ongoing Hudson's site project, the finished Book Tower restoration and the completed expansion to the back of One Campus Martius, formerly known as the Compuware Building. Contact JC Reindl: 313-378-5460 or jcreindl@ Follow him on X @jcreindl This article originally appeared on Detroit Free Press: Final details laid out for Gilbert's next downtown development
Yahoo
08-04-2025
- Business
- Yahoo
Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
CHICAGO, April 08, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the 'Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the launch of its Sky Premium Life food supplements brand in Albania, in partnership with Pharma Cell, a leading consumer health and medical supplement company that will serve as the distributor in the country. Cosmos Health has secured an initial annual order worth $300,000 and anticipates further scaling its collaboration with Pharma Cell over time. Pharma Cell, based in Tirana, is a fast-growing pharmaceutical company specializing in the import and export of high-quality food supplements. Founded in 2021 by CEO Elvis Punmira, an economist with over 18 years of industry experience, the company builds on a family legacy in the pharma sector dating back to the 1990s. With distribution rights for several international brands, Pharma Cell has rapidly expanded its presence across the country, serving a growing network of pharmacies and healthcare professionals. Greg Siokas, CEO of Cosmos Health, stated: "Sky Premium Life continues to see strong international growth, and it's a great pleasure to welcome our new collaboration with Pharma Cell. We look forward to working together to deliver outstanding results and establish the brand's presence in Albania.' About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at as well as LinkedIn and X. Forward-Looking StatementsWith the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:BDG Communicationscosm@ +44 207 0971 653Sign in to access your portfolio
Yahoo
06-02-2025
- Business
- Yahoo
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar
CHICAGO, IL / / February 6, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an initial purchase order of $578,460 from Al Rabwa International Services and Trading ("Al Rabwa") for its Sky Premium Life® food supplement products in Qatar. The initial purchase order covers 35 of the Company's 79 SKUs. Al Rabwa has been granted exclusivity, and the Company looks forward to strengthening this partnership through additional future orders. Established in 2013, Al Rabwa has successfully evolved into one of the leading distribution companies in Qatar, catering to retail, food service, and wholesale sectors. Al Rabwa's extensive product portfolio is backed by a network of reputable global suppliers and producers, complemented by a professional, world-class approach to sales, marketing, and customer service - giving the company a leading edge in Qatar's distribution space. Greg Siokas, CEO of Cosmos Health, stated: "We are delighted to announce our first order from Al Rabwa, allowing us to capitalize on Qatar's rapidly expanding market. This is another important partnership for Cosmos and a testament to the high quality of our products and the strong global demand they continue to attract." About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at as well as LinkedIn and X. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact: BDG Communicationscosm@ 207 0971 653 SOURCE: Cosmos Health Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Associated Press
05-02-2025
- Business
- Associated Press
Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market
CHICAGO, IL / ACCESS Newswire Cosmos Health Inc. ('Cosmos Health' or the 'Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of a patent application for multiple sclerosis (MS), a disabling autoimmune disorder affecting millions worldwide. The patent application, filed under Application Number N2039644, represents a significant step forward in the Company's intellectual property strategy. This milestone highlights Cosmos Health's strategic partnership with Cloudpharm and the National Hellenic Research Foundation, supported by the pharma patent expert team at NLO. The patent is supported by data-driven in silico evidence and simulations generated by Cosmos Health's AI-powered Cloudscreen drug repurposing platform, coupled with robust experimental validation. Recent findings by Cosmos Health have demonstrated the potential of a repurposed marketed drug for treating MS, with the inventors identifying a unique mechanism of action. These advancements underscore the Company's commitment to tackling the challenges of autoimmune diseases and providing innovative solutions to enhance patient care. Multiple Sclerosis Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, causing a wide range of symptoms and significant disability. According to the Atlas of MS, the number of individuals living with MS globally has risen from 2.3 million in 2013 to 2.9 million in 2023. With its unpredictable progression, MS presents ongoing challenges for patients and healthcare providers alike. Global Market Overview According to Grand View Research, the global multiple sclerosis treatment market has been experiencing steady growth, driven by advancements in therapeutic options and a rising prevalence of the disease. The market was valued at approximately $25.94 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2030. This growth is fueled by the introduction of innovative therapies, increased healthcare investments, and ongoing research to address the unmet needs of MS patients. Greg Siokas, CEO of Cosmos Health, stated: 'This patent application is another important addition to our intellectual property portfolio and reflects our dedication to advancing innovative treatments for complex diseases. By focusing on multiple sclerosis, we are addressing a critical medical need and are committed to delivering impactful solutions for patients worldwide.' About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at as well as LinkedIn and X. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words 'believes,' 'expects,' 'anticipates,' 'intends,' 'projects,' 'estimates,' 'plans' and similar expressions or future or conditional verbs such as 'will,' 'should,' 'would,' 'may' and 'could', are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise. +44 207 0971 653
